Transplant survival rates decreased significantly (43%) when patients had abnormal or diseased aortic valves before receiving an LVAD

More and more, physicians are using the left ventricular assist device, or LVAD, to sustain patients who are awaiting heart transplants. The surgically implanted mechanical device takes over for weak and diseased hearts, acting as a bridge to transplant surgery. For the LVAD to work optimally, however, the aortic valve, which releases oxygen-rich blood from the heart into the body, must be free from disease.

In a study presented today at the International Society of Heart and Lung Transplantation, Temple University researchers reported that survival to transplant rates decreased significantly (43%) when patients had abnormal or diseased aortic valves before receiving an LVAD.

Lead author Erika Feller, M.D., a cardiology fellow at Temple University School of Medicine and Temple University Hospital, found conversely that the majority of patients (76%) who had normal aortic valves before receiving the LVAD survived to transplant.

“What this study might tell us is that patients need to have abnormal valves surgically repaired during the LVAD insertion, or we need to upgrade their listing on the transplant waiting list,” said Feller.

“Most patients in need of heart transplants have very sick hearts with valves that aren’t working well. While the LVAD can be a great help to these patients, it’s important that we also optimize their chances of survival to transplant by fixing such problems as a diseased aortic valve,” she said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients